Oncorena develops a completely new and potentially revolutionizing treatment for patients with metastatic kidney cancer. The drug is based on the natural substance orellanine, found in certain mushrooms known to cause kidney damage to persons who eat them.In experiments we have demonstrated that orellanine kills also kidney cancer cells and this will now be verified in patients.
Impact: New treatment for metastasized renal cancer
Location: Sweden, Lund
Total raised: $2.65M
Investors 1
| Date | Name | Website |
| - | GU Venture... | guventures... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| - | - | $2.65M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 04.09.2023 | Oncorena’s First Patient Treated with ONC175 (orellanine) in... | Oncorena’s First Patient Treated with ONC175 (orellanine) in clinial phase I/II trial in Patients wi... | news.cisio... |
| 20.06.2022 | Börje Haraldsson appointed CEO of Oncorena AB | Börje Haraldsson appointed CEO of Oncorena AB Mon, Jun 20, 2022 08:30 CET Report this content LUND, ... | news.cisio... |
| 01.02.2022 | Oncorena Initiates the Phase I-II Clinical Trial with Orella... | Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients ... | news.cisio... |
| 23.12.2021 | Oncorena Secures Financing of the Company's Continued Develo... | LUND, Sweden, Dec. 23, 2021 /PRNewswire/ -- Oncorena, developing a potential breakthrough therapy fo... | marketscre... |
| 23.12.2021 | Oncorena AB announced that it has received SEK 66 million in... | Oncorena AB announced that it has received SEK 66 million in funding on December 23, 2021. The trans... | marketscre... |
| 23.12.2021 | Oncorena Secures Financing of the Company's Continued Develo... | LUND, SWEDEN, December 23, 2021 - Oncorena, developing a potential breakthrough therapy for advanced... | marketscre... |
| 23.12.2021 | Oncorena Secures Financing of the Company’s Continued Develo... | Oncorena Secures Financing of the Company’s Continued Development of Orellanine, a Potential Breakth... | news.cisio... |
| - | HealthCap makes 104th investment as Swedish company Oncorena... | Gothenburg, Sweden, September 29, 2016 Oncorena secures MSEK 24 for clinical studies of metastasi... | healthcap.... |
| - | Oncorena Initiates the Phase I-II Clinical Trial with Orella... | LUND, SWEDEN, February 1, 2022 – Oncorena today announced the initiation of the Phase I-II clinica... | healthcap.... |
| - | Oncorena Secures Financing of the Company’s Continued Develo... | LUND, SWEDEN, December 23, 2021 – Oncorena, developing a potential breakthrough therapy for advanced... | healthcap.... |
Show more